Shilpa's CDMO customer placed binding purchase order

Shilpa Biologicals files Type IV DMF of recombinant Human Albumin 20% with USFDA

This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process

Shilpa Pharma Lifesciences’ Unit II, Raichur, Karnataka clears PMDA Japan, GMP inspection

The inspection has concluded successfully on 1st September 2023 without any critical/major observation

ShilpaMedicare Q1FY23 consolidated PAT drops to to Rs. 84.85 lakhs

Mylab partners with Shilpa Biologicals for vaccines and therapeutics segment

Shilpa Biologicals has tie-ups with Zydus to supply ZyCoV-D vaccine drug substance and Dr Reddy’s to make Sputnik V from its facility in Dharwad

Zydus supplies first consignment of its Covid-19 vaccine ZyCoV-D

The vaccine will be priced at Rs. 265 per dose and the applicator being offered at Rs. 93 per dose excluding GST

Shilpa Biologics permitted to conduct Phase 1 study on NavAlbumin

The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent